Miltenyi Biotec

Bergisch Gladbach, Germany
CAR-T Cell Therapy
8 confirmed programs · 8 sponsors · Last scored 2026-04-29
74.6
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (16) ✓ EMA GMP (2) ○ MHRA GMP

Quick Facts: Miltenyi Biotec

Signal Score
74.6/100 (as of 2026-04-29)
Quality Compliance
100.0/100 — No FDA inspection records found for this manufacturer
Headquarters
Bergisch Gladbach, Germany
Modalities
CAR-T, Cell Therapy
Active Programs
8 confirmed from ClinicalTrials.gov across 8 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Miltenyi Biotec

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 100.0
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Source: FDA Data Dashboard
No FDA inspection records found for this manufacturer · Quality score requires FDA inspection data
FDA InspectionsNo US records on file
EMA GMP Certificates2 on record
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 57.5
8 active programs across 8 sponsors
Modalities: Cell Therapy, CAR-T
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
8 active programs across 8 sponsors · Modalities: Cell Therapy, CAR-T · 2 programs in advanced phases (Phase 2/3)
Programs 8
Sponsors8
ModalitiesCAR-T, Cell Therapy
8 active programs across 8 sponsors
Modalities: Cell Therapy, CAR-T
2 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease PHASE1 Recruiting
NCT05705570 Clinical Trial Using CAR- T Cells for Treatment of Patients... PHASE1 Recruiting
NCT05094206 CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies PHASE1 Terminated
NCT05281809 Local Manufacture of CAR T-Cell Products for the Treatment of... PHASE2 Recruiting
NCT04464434 Upfront Autologous HSCT Versus Immunosuppression in Early... PHASE4 Completed
NCT01033617 IMPACT-CABG Trial: IMPlantation of Autologous CD133+ sTem... NA Completed
NCT00595127 Hematopoietic Stem Cell Transplantation for Treatment of... NA Completed
NCT01881334 Expanded Access to T-cell Depleted Haplo-Identical Stem Cells... NA Available
Source: ClinicalTrials.gov · Retrieved Jul 04, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 66.0
Strong partnership activity (6 articles)
Regulatory milestones (6 articles)
Sites: Bergisch Gladbach, DE
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press16 articles
Strong partnership activity (6 articles)
Regulatory milestones (6 articles)

Miltenyi Biotec EMA GMP Compliance 2 certificates

2025-06
2024-09
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_NW_04_GMP_2025_0046 Miltenyi Biotec B.V. & Co. KG Germany 2025-06-18 COMPLIANT
DE_MV_01_GMP_2025_0017 Miltenyi Biotec B.V. & Co. KG Germany 2024-09-19 COMPLIANT
Source: EMA EudraGMDP · Retrieved Jul 04, 2026

Recent News 16 articles

general 2026-05-06
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc. - openPR.com
GMP Cytokines Market Key Players | Miltenyi Biotec, ABCAM, Akron Biotech, REPROCELL Inc etc.  openPR.com
Source →
partnership 2026-04-28
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing - koreabiomed.com
CHA Biotech, Miltenyi Biotec collaborate on scalable CAR-NK manufacturing  koreabiomed.com
Source →
partnership 2026-04-28
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ  Chosunbiz
Source →
partnership 2026-04-28
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy - aju press
Cha Biotech Partners With Miltenyi Biotec to Develop Allogeneic CAR-NK Cancer Therapy  aju press
Source →
partnership 2026-04-28
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ - Chosunbiz
Cha Biotech partners with Miltenyi Biotec to advance CAR-NK therapy in Korea - CHOSUNBIZ  Chosunbiz
Source →
partnership 2026-04-27
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform  Manufacturing Chemist
Source →
partnership 2026-04-27
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform - Manufacturing Chemist
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform  Manufacturing Chemist
Source →
regulatory 2026-04-26
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
regulatory 2026-04-26
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
regulatory 2026-04-25
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
regulatory 2026-04-24
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
regulatory 2026-04-18
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
regulatory 2026-04-14
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy - MSN
BIRAC in pact with Miltenyi Biotec India to boost India's capabilities in cell & gene therapy  MSN
Source →
general 2026-02-23
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation - ET Pharma
Miltenyi Biotec sprints for the CAR-T finish line amid rising Big Pharma consolidation  ET Pharma
Source →
general 2026-02-20
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential - Business Standard
Miltenyi Biotec weighs local CGT manufacturing, eyes export potential  Business Standard
Source →
regulatory 2026-02-20
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies - Moneycontrol.com
Miltenyi Biotec sees big India opportunity as it advances Made‑for‑India CAR‑T therapies  Moneycontrol.com
Source →

Frequently Asked Questions About Miltenyi Biotec

Does Miltenyi Biotec hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Miltenyi Biotec.
How many clinical programs is Miltenyi Biotec linked to?
Miltenyi Biotec is associated with 8 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Miltenyi Biotec's CDMO Signal Score?
Miltenyi Biotec has a Signal Score of 75/100, based on quality, operations, financial stability, and capacity data.
Evaluating Miltenyi Biotec for a manufacturing program?
Use the free AI matchmaker to compare Miltenyi Biotec against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.8
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 83.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy